Thursday, October 2, 2014

Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy

TEL AVIV, ISRAEL -- Compugen Ltd. (NASDAQ: CGEN) today disclosed results from recent studies further confirming CGEN-15049 as a promising target candidate for cancer immunotherapy. These recent studies evaluated the function of this Compugen-discovered immune checkpoint candidate on immune cells derived from the tumor environment of melanoma patients. Based on these and earlier experimental results, CGEN-15049, which is expressed on various cancers including lung, ovarian, breast, colorectal, gastric, prostate and liver, is further advancing in the Company’s Pipeline Program, with ongoing therapeutic antibody development activities against this novel target.

Europe’s Largest Independently Owned Car Dealership Chooses Oncam Grandeye 360-Degree Technology

LONDON -- Oncam Grandeye, the security division of Oncam Technologies, has been selected by Pelco by Schneider Electric and its integrator, Assure Alarms, to supply 360-degree camera technology across Arnold Clark’s 200 U.K. showrooms. The system was trialed for six months and now, Robert Bryce, the head of security for the car dealership, plans to continue using the leading 360-degree surveillance solution for both interior and outdoor locations. “We like the system,” he says. “It’s more user-friendly, discreet, and easier to maintain than any other camera we’ve seen. Oncam Grandeye has a good product and good service, and we’re very happy with the combination,” he added.

TxCell to Present Latest Developments of Personalized Cell-Based Immunotherapy Platform, ASTrIA, at the 13th BIO Investor Forum 2014

VALBONNE, FRANCE -- TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US. The 13th Annual BIO Investor Forum, hosted by the Biotechnology Industry Organization (BIO), features leading private and emerging public companies. TxCell’s presentation is scheduled for Wednesday, October 8, 2014 at 12:00 p.m. PT at the Sea Cliff Room of the Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, US.

PharmaVentures Acts As Advisor to Plethora Solutions in Deal with Recordati

OXFORD, UK -- PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation. Under the terms of the agreement Plethora are expected to receive upfront and milestone payments of up to €46 million plus royalties. Stephen Waterman, Vice President, who led the PharmaVentures team on the deal commented: "We are delighted to have worked with Plethora on the deal terms of this important licensing agreement".

Pharmacogenetic Test Neurofarmagen® Arrives in Italy

BACELONA, SPAIN -- The Spanish biotech company AB-Biotics, traded on the Spanish Alternative Stock Market (MAB), and FB Health reached an agreement to launch the pharmacogenetic test Neurofarmagen® en Italy. FB Health, focused on neurology and founded by Dr. Francesco Bellini -founder of pharmaceutical companies such as BioChem-, has launched this month the analysis in the Italian market, where about 9 million people have suffered a mental disorder at least once in their lives. The company will present Neurofarmagen® in the National Congress of the Italian Society of Psychopathology (SOPSI) to be held next February in Milan.

Tuesday, September 30, 2014

NC COIN Launches New Website

RESEARCH TRIANGLE PARK & GREENSBORO, N.C. -- NC COIN (North Carolina Center of Innovation Network) has launched its new website, NCCOIN.org, to provide access to educational and networking resources and showcase its new look designed to highlight the organization’s mission to accelerate ideas, drive business, and establish a culture for growth. Formerly the North Carolina Center of Innovation for Nanobiotechnology, NC COIN has changed its name to reflect its true mission, promoting innovative technologies in the areas of biotech, nanobio, agbio, advanced materials and medical devices, all of which use Nanobiological techniques and tools.

Blackstone NC Executive Director Bob Creeden Moderates Coastal Connect Conference Panel

WILMINGTON & DURHAM, N.C. -- Bob Creeden, executive director of The Blackstone Entrepreneurs Network of North Carolina (Blackstone NC), moderated the panel “Who Are the Statewide North Carolina Leaders in Life Sciences?” at the recent Coastal Connect Entrepreneur and Capital Conference in Wilmington. The hugely successful event, hosted by the UNC-Wilmington’s Center for Innovation and Entrepreneurship (CIE), was one of several influential conferences involving Blackstone NC in September.